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Summary 
Background: Mistletoe is often used as a complementary ap-
proach in oncology. Despite experimental anti-tumour effects and 
several reviews there remains controversy about its clinical role. 
Patients and Methods: Potentially relevant trials were identified to 
perform a systematic review (databases: e.g. EMBASE, MEDLINE; 
hand search: e.g. bibliographies; search terms: e.g. mistletoe). 
To be included, randomised or comparative clinical trials at least 
had to examine mistletoe preparations standardized according to 
manufacturing process and to describe interventions explicitly. 
Additionally, cohort studies were included for reasons of external 
validity. Results were summarised in tables. Results: 18 clinical tri-
als (>6,800 participants) were included. Their internal quality was 
mostly low. Due to heterogeneity between trials a meta-analysis 
was impossible. Regarding efficacy, findings were inconsistent re-
garding life expectancy, relation to tumour entity, dosing and treat-
ment duration. Yet, studies indicate that quality of life (QoL) is im-
proved. As these findings do not seem to be limited to one of the 
different parenteral mistletoe preparations reviewed the treatment 
may be summarised under the umbrella term ‘mistletoe therapy’. 
Regarding safety, 1 serious adverse event (AE) related to mistletoe 
was described; non-serious AEs were local reactions at injection 
site. Allergic reactions were rare. Conclusion: Supportive ‘mistletoe 
therapy’ seems safe and beneficial for QoL in adult patients with 
solid tumours. But there is an urgent need to confirm its efficacy in 
patient-centred care in a complex oncological setting. This has to 
be evaluated systematically in prospective observational trials with 
validated, multidimensional patient-rated QoL questionnaires and 
comparisons of different preparations and dosages. 
Schlüsselwörter 
Mistel · Viscum album · Komplementärmedizin · Onkologie ·  
Anthroposophische Medizin · Phytotherapie · Systematisches  
Review · Supportiv 
Zusammenfassung 
Hintergrund: Mistelzubereitungen werden oft als komplementärme-
dizinischer Ansatz in der Onkologie eingesetzt. Trotz experimentel-
ler Anti-Tumoreffekte und einigen Reviews ist ihr klinischer Stellen-
wert umstritten. Methode: Potenziell relevante Studien wurden aus-
gewählt, um ein systematisches Review zu erstellen (Datenbanken: 
z.B. EMBASE, MEDLINE; Handsuche: z.B. Bibliographien; Such-
begriffe: z.B. Mistel). Um eingeschlossen zu werden, mussten die 
randomisierten oder vergleichenden Studien Mistelzubereitungen 
untersuchen, die zumindest auf den Herstellungsprozess standar-
disiert waren und die Intervention genau beschrieben. Zusätzlich 
wurden Kohortenstudien zwecks externer Validität eingeschlossen. 
Die Ergebnisse wurden in Tabellen zusammengefasst. Ergebnisse: 
18 klinische Studien (>6800 Teilnehmer) wurden eingeschlossen. 
Ihre Qualität war meist niedrig. Aufgrund der Heterogenität der 
Studien war keine Metaanalyse möglich. Hinsichtlich Wirksamkeit 
waren die Ergebnisse uneinheitlich in Bezug auf Lebenserwartung, 
Tumorentität, Dosierung und Behandlungsdauer. Jedoch ergab 
sich aus den Studien ein Hinweis auf die Verbesserung der Lebens-
qualität (QoL). Da diese Resultate nicht auf eine der verschiedenen 
parenteralen Mistelzubereitung begrenzt zu sein scheinen, können 
die Interventionen unter dem Sammelbegriff «Misteltherapie» zu-
sammengefasst werden. Hinsichtlich Sicherheit wurde 1 schwer-
wiegendes unerwünschtes Ereignis (UE) mit Bezug zur Mistelbe-
handlung berichtet, nicht schwerwiegende UE waren lokale Reak-
tionen an der Injektionsstelle. Allergische Reaktionen waren selten. 
Schlussfolgerung: Die supportive «Misteltherapie» scheint sicher 
und die Lebensqualität erwachsener Patienten mit soliden Tumoren 
zu verbessern. Jedoch gibt es dringenden Forschungsbedarf, um 
die Wirksamkeit im Rahmen eines patientenzentrierten komplexen 
onkologischen Settings zu evaluieren. Dies sollte systematisch in 
prospektiven Anwendungsbeobachtungen, mit verschiedenen Do-
sierungen und Behandlungsdauern, anhand validierter, multidi-
mensionaler, von Patienten ausgefüllten Fragebögen zur Lebens-
qualität evaluiert werden.
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Introduction 
There is a long tradition of using a variety of preparations 
made from European mistletoe (Viscum album L.) as folk 
remedies (e.g. its oral and topical use in ancient Greek and 
Celtic medicine) [1]. However, modern parenteral use of mis-
tletoe extracts for patients with cancer was initiated in the 
1920s by Rudolf Steiner (1861–1925) in the context of anthro-
posophic medicine [2, 3]. On the basis of humanistic consider-
ations, Steiner saw analogies between the aetiology and course 
of cancer on the one hand and growth principles of mistletoe 
on the other hand. Steiner developed anthroposophic medi-
cine together with the physician Ita Wegman (1876–1943). 
Wegman herself made the first mistletoe preparation (‘Iscar’), 
a precursor of today’s Iscador brand preparations and used it 
starting in 1917 in cancer patients in Zurich. In keeping with 
the anthroposophic view of disease and medicinal doctrine, a 
sort of immune modulating action was postulated as the active 
principle, plus both direct and indirect inhibitory effects on 
tumour growth. In the following decades, other companies de-
veloped different mistletoe preparations. Therefore, mistletoe 
preparations from the field of anthroposophic medicine and 
from the field of phytotherapy are available today (table 1).
A considerable percentage of patients with cancer include 
treatments from complementary and alternative medicine 
(CAM) in their therapeutic approach along with oncological 
therapies. Respective surveys indicate a prevalence of 14.8–
91% for the use of CAM [4–8]. Yet, considering such a broad 
range, one should bear in mind that most of the surveys are 
not representative (e.g. different definitions of CAM, various 
survey methods as well as socio-cultural contexts, economic 
status and health care systems) [6, 9, 10]. Nevertheless, in 
German-speaking countries (Austria, Germany, Switzerland) 
parenteral mistletoe preparations traditionally are one of the 
most commonly used CAM treatments of patients with cancer 
diseases along with their standard oncological treatment [4, 
5] and non-representative data suggest a prevalence of its use 
between 29–77% [4, 8, 11]. Yet, differences between countries 
have to be considered (patients’ use: e.g. 0% reported in hos-
pitals in Turkey [12] or Japan [13], but 96% in an anthropo-
sophic hospital in Switzerland [14]).
In order to bridge the gap between traditional use and cur-
rent research evidence of mistletoe preparations we thought it 
was necessary to systematically review efficacy and safety of 
mistletoe preparations in clinical trials, to give a short over-
view on the possible mechanisms of action and to outline clini-
cally useful prerequisites for future research while taking into 
account the patients’ perspective.
Aspects of Mistletoe, Its Preparations and Treatment
Mistletoe, Viscum album [L.], is a plant with a partially woody 
stem that, as a semi-parasite, lives epiphytically on the branches 
of a variety of deciduous and coniferous trees. The herbal drug 
used is defined as the stems and leaves. From this raw mate-
rial various commercially available preparations are made (e.g. 
pressed sap or extract). Mistletoe extracts are complex herbal 
preparations (i.e. multi-compound), contain various biologi-
cally active substances, and their content may vary depending 
on harvest time, species of the host tree and manufacturing 
process [16–18]: e.g. mistletoe lectins (ML), viscotoxins, amino 
acids, flavonoids, phenylpropanoids, triterpenes, phytosterol, 
alkaloids, polyalcohols, polysaccharides. The different fractions 
Table 1. Different mistletoe preparations used in the clinical trials reviewed (given in various dosages)
Preparation Extract Host tree Application Dosage  
(mg extract or ng ML)
Standardisation
Phytotherapeutic preparations
Eurixor® aqueous (herb) poplar subcutaneous,
s.c. (i.c., i.v.)
1 mg or 70 ng / ampule (1 ml) (ML-I) 
Lektinol® aqueous (herb) poplar s.c. (i.v.) 0.02–0.07 mg or 15 ng / ampule 
(0.5 ml)
ML-I
Anthroposophic preparations
Helixor® aqueous (herb) apple (M: Malus), 
fir (A:. Abies), 
pine (P: Pinus)
s.c. 0.01–50 mg / amp. (1 ml),
100 mg (2 ml)
process
Iscador® aqueous lacto-fermented 
(herb) 
M, P, A,
elm (U: Ulmus),
oak (Q: Quercus)
s.c. 0.0001–20 mg 
/ ampule (1 ml)
process
Isorel® aqueous (planta tota) M, P, A s.c.; i.m. 1–60 mg process
*E.g. no clinical trials with Iscador M specified 1–5 mg extract (50–250 ng ML) with a lectin content defined as total lectin content analysed by 
ELISA-Test with ML II as standard.
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Tab. 2. Summary of clinical trials with mistletoe therapy - listed according to different preparations 
Reference Type of 
study 
Diagnosis / 
therapeutic 
indication 
Patients 
included n / 
analysed (n) 
Treatment Results Statistics AE / side-effects Notes 
Eurixor (EUR) 
RCT / CT 
Goebell  
et al. 
2002(62) 
prospective, 
randomised, 
ctrl  
 
Phase II 
 
(3 years) 
superficial bladder 
ca, relapse 
prophylaxis after 
transurethral 
resection 
  
(pTa stage 1-2) 
 
(adjuvant 
mistletoe therapy) 
n = 45 (44) total 
 
n = 23 (23) EUR 
 
n = 22 (21) Ctrl 
(after 3 mo n = 21 
due to 1 death) 
 
duration: 3 mo EUR, 
3 mo break EUR, 
then 2nd cycle 
EUR:  
1 ml EUR 2/wk s.c. for 3 
months (= 1st cycle, 3 mo 
break, then 2nd cycle) 
 
Ctrl: 
untreated 
1) relapse-free interval 
EUR: 6.4 mo, ctrl: 6.3 mo 
 
2) additional: 
relapses after 18 mo: 
EUR: 31 vs Ctrl: 30 
 
disease-free survival: 
EUR: 9 mo, Ctrl: 10.5 mo 
no statistical 
comparison 
 
EUR: 
none observed 
 
Ctrl: 
1 death not related to disease 
or therapy 
no data on: study 
location, study period, 
ITT/PP, target 
parameters, 
preparation name 
(ascertained indirectly), 
dropouts 
Steuer-Vogt 
et al. 
2001(72) 
prospective, 
randomised, 
ctrl, multi-ctr, 
phase III 
 
A: 1993-1996 
B: 1993-1997 
 
head and neck 
ca: 
(T1-T4, N0-N3) 
 
 (adjuvant 
mistletoe therapy) 
 
n = 588 total 
n = 495 randomised 
(477) 
 
A: 
n = 202 
Ctrl: n =104/105 
EUR: n = 97 
 
B: 
n = 275 
Ctrl: n = 137 
EUR: n = 138 
 
ITT: n = 477  
PP: n = 364 
 
duration: 60 wks 
A:  
Ctrl: Op (tumour resection 
or unilateral or bilateral 
neck dissection) 
EUR: OP + EUR 
 
B: 
Ctrl: OP + RTX (50–75 
Gy) 
EUR: OP+ RTX (see 
above) + EUR (1 ng ML-
I/kg BW, 2/wk s.c. for 60 
wks, in intervals of 12 wks 
EUR and 4 wks pause) 
1) disease-free survival (5 y):  
ITT: hazard ratio 0.96 (95% CI: 0.73-
1.27; 200/477 = 42% relapse after 4 
y) 
PP: 0.88 (95% CI 0.63-1.21) 
 
2) disease-spec. survival (5 y):  
PP: 0.96 (95% CI 0.66-1.38) 
 
additional Information: 
immune parameters (n = 230): CD3+, 
CD4+, CD8+, CD19+, CD16+56+3+ 
 
Quality of life (n = 443): (EORTC-
QLQ-C30)* 
 
 
 
n.s. 
 
n.s. 
 
 
n.s. 
 
 
 
 
n.s. 
 
 
 
n.s. 
local or systemic side effects 
with start of the EUR injection: 
A: n = 47 (initially 48%; after 
32 wk 1-4%) 
B: n = 54 (initially 39%; after 
32 wk 4-8%) 
 
most common ADR:  
redness: 
A: n = 44 (initially 45%; after 
32 wk 1-4%) 
B: n = 54 (of 39%; to 1-5%) 
pruritis: 
A: n = 29 (initially 30%; after 
32 wk 1-3%) 
B: n = 41 (from 30% to 3-7%)  
Induration: 
A: n = 6 (initially 6%; after    
≥22 wk 1-5%) 
B: n = 11 (of 8%; to 1-5%) 
 
general drug reactions:  
myalgia, fever, insomnia, 
fatigue, feeling cold/hot, 
sneezing 1-4% 
 
EUR injections discontinued 
due to ADR: 
A: n = 16 (16%) 
dropouts: 
18 (unclear: A: Ctrl (n = 
104/105) 
 
protocol violations 
during the first 
treatment n = 48 
 
ethics committee 
rejected blinding due to 
frequent local reactions 
under EUR 
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Reference Type of 
study 
Diagnosis / 
therapeutic 
indication 
Patients 
included n / 
analysed (n) 
Treatment Results Statistics AE / side-effects Notes 
B: n = 27 (20%) 
Heiny et al. 
1998(64) 
prospective, 
randomised, 
matched-pair 
advanced 
metastasised 
colorectal ca 
 
(adjuvant 
mistletoe therapy 
with CTX) 
n = 107 (79) total 
 
n = 41 Ctrl (= A) 
 
n = 38 EUR (= B) 
 
duration: 8 wks 
therapy + 4 wks 
break (repeated 
multiple times until 
42nd wks) 
Ctrl: 
CTX (5-FU 600 mg/m2 
5/wk + folic acid 200 
mg/m2 5/wk i.v.) 
 
EUR:  
CTX (see above) + EUR 
(0.5-1 ng ML-I/kg BW 
2/wk s.c.) 
1) QoL (FACT scale, sum score): 
EUR better than Ctrl (from 12th to 
42nd wk = end of study) 
 
2) additional information: 
survival time: 
EUR: 52.8 wk vs Ctrl: 50 wk 
 
duration of remission: 
EUR 23.1 wk vs Ctrl 21.4 wk 
 
progression-free interval: 
EUR 30.8 wk vs Ctrl 31.2 wk 
 
 
p = 0.0001 
 
 
 
n.s. 
 
 
n.s. 
 
 
 
n.s. 
total side effects in % (n = 
79): 
nausea, vomiting: III WHO 
n.s., EUR 14.4, Ctrl 16.1; 
diarrhoea: n.s., EUR 25 Ctrl 
29; 
hand-foot syndrome: n.s., 
EUR 0, Ctrl 3.2; 
breast pain: n.s. EUR 3.6, Ctrl 
4.5; 
mucositis III: frequency with 
EUR 17.9 vs Ctrl 25.8, p = 
0.03 (duration in d shorter 
with EUR 12.3 vs Ctrl 16.8, P 
= 0.03)&; 
leukopenia: p = 0.01, EUR 
32.1 vs Ctrl 38.7,; 
thrombopenia: n.s., EUR 10.7 
Ctrl 12.9 
dropouts: 
28 (reason: did not 
meet analysis criteria) 
 
no data on: decision of 
ethics committee, 
informed consent, 
study location/time, 
ITT/PP 
 
unclear: target 
parameters except for 
QoL 
Lenartz D et 
al.  
2000(81) 
follow-up to 
Lenartz 1996 
malignant glioma n = 38 total 
 
n = 20 (20) EUR 
 
n = 18 (18) Ctrl 
 
duration: 50 mo 
follow-up 
see below 1) Survival time: 
total: EUR 21.7 ± 3.7 mo vs Ctrl 17.3 
± 3.9 mo  
stratified (grade III-IV):  longer with 
EUR 20.05 ±3.5 mo vs Ctrl 9.9 ± 2.1 
mo 
 
2) relapse-free: 
total: EUR: 14.41 ± 2.7 mo vs Ctrl 
14.76 ± 3.6 mo  
stratified (grade III-IV): trend for EUR 
17.43 ± 8.2 mo vs Ctrl 10.45 ± 3.9 mo 
(relapse rate after 1 y: for both groups 
50%) 
 
 
n.s. 
 
 
p = 0.035 
 
 
 
n.s. 
 
 
 
n.s. 
no data 9 dropouts: see below 
 
no data on: 3 more 
patients, change in 
tumour grade, 
stratification, 
decision of ethics 
committee, informed 
consent, study 
location/time, ITT/PP, 
 
Kaplan-Meier survival 
curve in a pilot study 
Lenartz D et 
al. 1996(65) 
prospective, 
randomised 
 
(Pilot study 
1994-95) 
malignant glioma  
grade III/IV 
 
(immunomodulati
ng mistletoe 
therapy for neo-
adjuvant CTX) 
n = 35 (26) total 
 
n = 18 (13) EUR 
 
n = 17 (13) Ctrl 
 
duration: 3 mo 
therapy + 3 mo 
follow-up 
Ctrl: 
OP + perioperative DX 
(24 mg/d) + RTX (total 60 
Gy)  
 
EUR: 
OP + DX + RTX (see 
above) + EUR (from 1st d 
post-OP 1 ng ML-I/kg BW 
2/wk s.c.) 
1) Immune parameters:  
increase in CD-3+, CD-4+, CD-8+, CD-
25+ T-lymphocytes after 3 mo with 
EUR compared to pre-OP 
 
2) QoL (Spitzer index):  
trend: improvement with EUR 
 
 
 
p <0.05 
 
 
n.s. 
no data 9 dropouts: (reason: 
insufficient therapy and 
diagnosis schedule  
 
no data on:  
decision of ethics 
committee, informed 
consent, study 
location/time, ITT/PP 
Heiny  prospective, advanced breast n = 46 (40) total Ctrl:  1) Blood count:  EUR: dropouts: 
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Reference Type of 
study 
Diagnosis / 
therapeutic 
indication 
Patients 
included n / 
analysed (n) 
Treatment Results Statistics AE / side-effects Notes 
1991(82) randomised, 
pl-ctrl 
 
ca 
 
(additive mistletoe 
therapy with 
palliative CTX) 
 
n = 21 (19) Ctrl 
 
n = 25 (21) EUR 
 
duration: 6 intervals 
interrupted by 28-d 
pause 
CTX (VEC - 3, 40, 750 
mg/m2; 6 cycles with 28-
day break each) + pl 
(NaCl per infusion) + 
ondansetron (3 x 8 mg/d 
for 5 d) 
 
EUR:  
CTX + EUR i.v., (1st, 2nd, 
4th, 5th d each 1 ng ML-
I/kg BW per infusion in 
NaCl; then 1-2/Wo s.c.) + 
ondansetron (see above) 
recovery leukocytes from 2nd CTX 
cycle to approx. 2,800 with EUR; 
thrombocytes:  
 
2) Mental state index, anxiety index  
(each sum score): 
improved mental state index with EUR 
(after 6th cycle); 
decreaed anxiety with EUR (after 3rd 
cycle) 
 
p ≤ 0.001 
n.s. 
 
 
 
 
p ≤ 0.01 
 
p ≤ 0.01 
granulocytosis (up to 24 h 
after EUR) and elevated CRP 
(80% of the patients) 
 
moderate fever and flu-like 
symptoms (e.g. joint pain, 
chills, abnormal fatigue 13/21 
patients) 
 
(for skin reaction over 5 cm 
dose reduced to 1/wk)  
 
6 after the 1st cycle (= 
4 EUR, 2 Ctrl, reason: 
Tumour progression = 
dropout criterion) 
 
additional motivation of 
the patients in 
interviews 
 
pre-testing for allergy 
to EUR 
 
no data on: decision of 
ethics committee, 
informed consent, 
study location/time, 
ITT/PP 
Cohort studies (retrolective studies) 
Schumache
r et al. 
2003(83) 
retrolective, 
ctrl 
primary, not 
metastasised 
breast ca 
n = 1248 (689) 
 
n = 470 Ctrl 
 
n = 219 EUR 
 
Ctrl: 
standard (surgery, 
chemo-, radio-, hormone 
therapy) 
 
EUR: 
EUR (2 x 1 mL/wk) 
+ standard (see above) 
 
duration:  
EUR = 270 d 
 
follow-up: 
EUR = 284 d (median) 
Ctrl = 285 d (median) 
1) Change of disease/therapy related 
symptom score at start and end 
postoperative treatment: improvement 
except for dyspnoe at work, headache 
 
2) KPI: 
Ctrl = minus 7.5% ; EUR = plus 8.2% 
 
3) relapses: 
EUR = 6 (2.78%) vs Ctrl = 24 (5.22%) 
 
4) relapse-free time: 
EUR vs Ctrl 
(HR after multivariate adjustment) 
 
 
OR = 0.7133 (CI: 
0.65–0.77, p = 
0.0001) 
 
 
 
no data 
 
 
 
no data 
 
 
p = 0.0053 
(HR: 0.28, CI: 0.1–
0.76, p = 0.012) 
EUR-related: 
n = 28 (12.8%) 
randomisation limited 
to selection of centres 
 
n = 559 excluded due 
to protocol violations 
 
no data on: ITT/PP 
 
according to authors, 
the observation period 
relativises the 
statement on relapses 
 
Helixor (HEL) 
RCT 
Piao et al. 
2004(70) 
Prospective, 
multi-ctr., 
randomised, 
open, 
comparative 
study 
 
3 centres in 
breast, ovarian, 
non-small cell 
lung cancer 
(breast cancer n = 
68 
ovarian cancer n 
= 71 
n = 233 total (224) 
 
n = 118 (115) HEL 
 
n = 115 (109) Ctrl 
 
duration:  
HEL: 
CTX + HEL A, 3/wk s.c. 
starting with 1 mg to 200 
mg 
 
Ctrl 
CTX + lentinan 4 mg/d 
1) KPI (n = 223): 
increase HEL (n = 115)  50.4 % vs 
Ctrl (n = 108) (30.4 % 
 
2) TCM (sum score) (n = 220): 
decrease = improvement with HEL (n 
= 113) -1 point vs Ctrl (n = 107) 0 
points 
 
(stratified) 
p = 0.002 
 
 
(stratified) 
p = 0.0007 
 
AE 
total: 
HEL 52 vs Ctrl 90 (each 
symptom), 
related to CTX: 
HEL 28 vs Ctrl 77 
 
dropouts: no data 
 
excluded: 
9 patients (reason: no 
measured data, treated 
≤ 4 weeks) 
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Reference Type of 
study 
Diagnosis / 
therapeutic 
indication 
Patients 
included n / 
analysed (n) 
Treatment Results Statistics AE / side-effects Notes 
China 
 
2000-2001 
non-small cell 
lung cancer n = 
94) 
HEL 1-8 wks 
Ctrl 2-12 wks 
i.m. 
 
(CTX: 
breast cancer: 
adriamycin, cisplatin, 
cyclophosphamide, 5-FU 
 
ovarian cancer:  
carboplatin, cisplatin, 
cyclophosphamide, 
ifosfamid 
 
non-small cell lung 
cancer: cisplatin, 
mitomycin, vindesin, 
vinorelbine) 
 
3) FLIC ( n = 222): 
improvement with HEL (n = 115) 6 
points vs Ctrl (n = =107) 3 points 
 
(stratified) 
p = 0.014 
SAE: 
HEL 5 (1 HEL-related 
angioedema/urticaria - 
improvement after 2 d) vs 
Ctrl 10 (1 lentinan- related) 
related to CTX: 
HEL 2 vs Ctrl 4 
 
side effects  
HEL: 4 x fever, 7 x redness, 
pruritis at the injection site (no 
withdrawl) 
no data on: CTX dose, 
study location, 
validation of the TCM 
index, PP 
 
usual dosage for 
lentinan: 0.4− 4 mg/wk 
instead of 4 mg/d 
Douwes  
et al. 
1986(84) 
prospective, 
randomised 
metastasised 
colorectal ca  
 
(effect of 
biological 
response 
modifiers on 
duration of 
remission and 
QoL) 
n = 60 total 
 
n = 20 Ctrl (= A) 
 
n = 20 HEL (= B) 
 
n = 20 Ney (= C) 
 
duration: no data 
Ctrl: 
CTX (570 mg/m2 5-FU + 
200 mg/m2 folic acid i.v., 
1st-5th d, repeat after 5 d, 
5-16 cycles) 
 
HEL:  
CTX (see above) + HEL 
(increasing dose up to 
200-300 mg daily, s.c.) 
 
Ney:  
CTX (see above) + Ney 
(increasing dose to 30 mg 
2/wk i.v. or s.c.) 
1) Remission: 
A: 12/20 (60%) 3 CR, 6 PR, 3 MC vs 
B: 13/20 (65%) 3 CR, 7 PR, 3 MC vs 
C: 13/20 (55%) 3 CR, 5 PR, 5 MC 
 
2) mean survival time (CR, PR, NC = 
responders):  
A: 13.6 ±4.4 mo vs B: 26.7 ±11.9 mo 
vs C: 23.7 ±9.6 mo 
 
 
 
n.s. 
 
 
 
 
no stat. analysis 
CTX – side effects: 
stomatitis, diarrhoea, 
thrombopenia – more 
common in A than B and C 
(no more specific data), 
alopecia 
 
Most common side effect: 
nausea 
 
no withdrawal due to SAE 
uncertainties: 
patient figures 
(MC/NC), % figures, 
dosage HEL, target 
parameter, results 
 
no data on: decision of 
ethics committee, 
informed consent, 
study location/time, 
randomisation ITT/PP, 
stratification 
 
previous CTX:  
2-4 pat. in each group 
before ≥3 mo 
Iscador (ISC) 
RCT / CT 
Kleeberg  
et al. 
2004(57) 
prospective, 
randomised, 
ctrl 
 
(phase III) 
 
(EORTC 
18871;  
DKG 80-1) 
 
(1988-1996) 
primary 
melanoma stage 
II (Breslow 
thickness >3 mm) 
+ stage III 
(curative 
dissection of 
regional lymph 
node metastases) 
 
(adjuvant 
mistletoe therapy 
n = 830 (793) total 
 
EORTC 
n = 139 rIFN-α2 
n = 142 rIFN-γ 
n = 142 Ctrl 
 
DKG 
n = 101 rIFN-α2 
n = 102 rIFN-γ 
n = 102 Ctrl 
rIFN-α2b: 
OP (resection pr. 
melanoma or curative 
dissection ) + IF (1 MU 
s.c. every other d  for 1 y) 
 
r IFN-γ: 
OP (see above) + IF (0.2 
mg s.c. q.o.d. for 1 y) 
 
ISC:  
1) disease-free interval (DFI):  
IFN α and also γ vs Ctrl 
ISC vs Ctrl 
 
2) survival time:  
each treatment group vs Ctrl 
 
n.s. (p = 0.77) 
n.s. (p = 0.12) 
 
 
n.s. 
minor side effects: 
rIFN 
approx. 1/3 of the patients 
(fever, chills, night sweats, 
fatigue, muscle pain, joint 
pain, headache) 
 
grade 3-4 toxicity acc. to 
WHO and treatment 
discontinuation: 
rIFN-α2: 11/240 patients 
dropouts: no explicit 
info 
 
ineligible: 37/830 
(4.6%) 
 
eligibility not 
assessable: 13/830 
(1.6 %) due to 
insufficient 
documentation  
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Reference Type of 
study 
Diagnosis / 
therapeutic 
indication 
Patients 
included n / 
analysed (n) 
Treatment Results Statistics AE / side-effects Notes 
 
45 centres in 
13 countries 
 
 
after curative OP) n = 102 ISC 
 
duration: 1 y or until 
tumour progression; 
follow-up 8 yrs 
OP + ISC-M (0, then 0.01 
until 1 mg/mL q.o.d. for 
2/wk, 3-d break, repeat 
until 14 doses 20 mg/ml, 
7 d break) 
(4.6%) 
rIFN-γ: 19/244 patients (7.8%) 
ISC: 5/102 patients (4.9%) 
(e.g. due to anorexia, general 
malaise, depression, fever, 
local skin inflammation at the 
injection site) 
 
no data on: decision of 
ethics committee, 
informed consent, PP 
 
somewhat unclear: 
study design, patient 
numbers, data 
presentation, ITT, ISC 
dose 
 
randomisation for ISC 
discontinued after 8-
year recruitment phase 
Dold et al. 
1991(63) 
prospective, 
randomised, 
multi ctr., pl-
ctrl, 3-arm  
 
(stratification 
acc. to clinic 
and TNM) 
advanced 
inoperable non-
small cell 
bronchial ca  
stage Ia-IV 
(T1 N0 M0 to  
T3 N1-2 M1) 
 
(adjuvant therapy) 
n = 408 total (337) 
 
n = 114 ISC 
 
n = 110 Polyerga 
 
n = 113 pl 
 
duration: 1978-1987 
ISC: 
Qu c. Hg or U c. Hg (1 ml 
0.001-30 mg active 
substance - increasing 
dose 3/wk s.c.) 
 
Polyerga: 
1 ml (with 30 µg 
glucopeptides 1/wk i.m.) 
 
Ctrl: 
(Vit. B complex 2 ml 1/wk 
i.m.) 
1) median survival time (312/337): 
ISC 9.1 mo vs Polyerga: 9.0 mo or vs 
Ctrl: 7.6 mo 
 
2) tumour response 
 
3) subjective well-being (301/337): 
improvement with ISC 59% vs Ctrl 
45% (Polyerga 43%) 
 
4) QoL (physical complaints) 
 
 
n.s. 
 
n.s. 
 
 
 
p = 0.018 
 
 
n.s. 
 dropouts:  
71 justified 
 
study end:  
due to discontinuation 
of therapy n = 32/337; 
due to death 221/337 
Toelg et al. 
2005(85) 
prospective, 
non-
randomised, 
ctrl, post-
marketing 
surveillance 
gynaecological 
tumours after 
resection 
 
n = 128 
 
n = 107 (ITT) 
n = 53 Isc 
n = 54 Ctrl 
 
duration: 6 mo 
Isc:  
Isc (Iscador M) + CTX 
 
Ctrl: 
CTX 
1) overall health (Isc:Ctrl in %): 
worsened = 23:20 
stabilised = 26:43 
improved = 51:37 
 
2) mental condition: 
ISC = + 16.7% 
Ctrl = +   7.0% 
 
3) QoL: 
ISC = + 17% 
Ctrl = + 33% 
n/a ISC: n = 7 (11%) 
(fever, redness at the injection 
site) 
dropouts: 
n = 5 Isc 
n = 5 Ctrl 
 
died: 
n = 6 Isc 
n = 5 Ctrl 
 
baseline: Ctrl = ovarian 
ca 4 x more often 
 
ADR: ISC imprecise 
data; Ctrl no data 
Cohort studies (retrolective studies) 
Augustin et 
al. 2005(73) 
multicentre 
retrolective, 
ctrl, 
epidemiologic
resected primary 
malignant 
melanoma 
UICC/AJCC 
N = 783 (686 PP) 
n = 329 ISC  
n = 357 Ctrl 
 
ISC: 
OP + ISC (P, M or Q; s.c. 
2-3/wk, ≥3 mo) + chemo- 
(10 %), radio- (7.9 %), 
1) tumor-related survival: 
ISC =   8.9 % vs Ctrl = 10.7 % 
[adjusted: HR 0.41 (0.23 - 0.71)] 
 
 
p = 0.017 
p = 0.002 
 
ISC related (adjusted): 
systemic reactions = 11 
(3.3%) 
local react., = 42 (12.8%) 
dropouts: 5 due to local 
reaction; 
2 due to syst. reaction 
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Reference Type of 
study 
Diagnosis / 
therapeutic 
indication 
Patients 
included n / 
analysed (n) 
Treatment Results Statistics AE / side-effects Notes 
al cohort 
study 
stages II-III  
 
(adjuvant therapy) 
centres = 35 
 
duration: 6 mo 
 
follow-up: ≥ 3 yrs (or 
death) 
immuno- (9.1 %), 
chemo/immunotherapy 3 
%) 
 
Ctrl: 
OP + watchful waiting + 
chemo- (5.9 %), radio- 
(5.9 %), immuno- (17.6 
%), chemo / 
immunotherapy 2.2 %) 
2) overal survival (adjusted HR): 
overall = 0.64 (0.42 - 0.96) 
disease-free = 0.73 (0.55 - 0.97) 
 
 
p = 0.033 
p = 0.029 
 
WHO/CTC grade: 1-2 
dropouts = 6 (1.2%) 
 
no indication of tumour 
enhancement; decreased HR 
for brain metastasis (HR = 
0.33; CI 0.13-0.86; p = 0.024) 
no data on: dosage, 
ITT, PP 
 
according to authors: 
significance of  study 
type limited in terms of 
survival 
Bock et al. 
2004(69) 
multicentre, 
retrolective, 
ctrl, 
epidemiologic
al cohort 
study 
 
 
resected primary 
non-metastasised 
breast carcinoma 
UICC/AJCC 
stages I-III  
 
(adjuvant therapy) 
n = 1442 total 
n = 710 ISC 
n = 732 Ctrl 
 
centres = 16 
 
evaluation = PP 
 
duration:  52 mo 
 
observation:  
ISC = 81 mo 
Ctrl = 52 mo 
ISC: 
standard + ISC, s.c., 2-3 
x / wk, ≥ 3 mo 
 
Ctrl: 
standard (chemo-, radio- 
and hormone therapy) 
 
follow-up observation 
period:  
≥ 3 y.; median = 61 or 67 
mo 
1) symptom-free at aftercare: 
(in particular: concentration, 
exhaustion, depression, sleep) 
ISC = 78% vs Ctrl = 39% 
 
2) survival time  (overall, adjusted): 
ISC vs Ctrl 
 
p = 0.0001, OR: 
0.47 (CI: 0.32-
0.67) 
 
 
p = 0.038 
HR = 0.46 (CI: 
0.22-0.96) 
disease-related (adj.): 
ISC = 16.3% 
Ctrl = 54.1% 
 
ISC-related: 
syst. react.  6/710 = 0.8% 
local react.123/710 = 17.3% 
 
no indications of tumour 
enhancement 
dropouts:  
ISC: n = 4 
 
not randomised,  
 
baselines differ 
change of treatment 
ISC: n = 7 
 
prospective, 
matched-pair  
(patients from 
retrolective 
cohort study 
with 10,226 
patients: 1668 
Iscador, 83 
other 
mistletoe 
preparation, 
8,475 no 
mistletoe) 
different tumour 
entities 
n = 98 total 
   = 49 pairs 
(n = 78 or 39 pairs) 
 
n = 39 ISC 
 
n = 39 Ctrl 
 
ITT: not analysed 
 
PP: no data 
 
duration: 1973-1982 
ISC:  
ISC - no data on dose or 
other therapies 
 
Ctrl:  
no Iscador; no data on 
other therapies 
1) change to the value for 
psychosomatic self-regulation (T 0 vs 
T 3 mo):  
ISC increase from 3.41 to 3.87 vs Ctrl 
decline from 3.85 to 3.62 
 
2) mean survival time:  
ISC longer (3.49 a) vs Ctrl (2.45 a)  
 
 
 
 
p = 0.022 
 
 
p = 0.04 
no data dropouts: 
1 fatality before 
therapy 
9 due to lack of 
consent by the doctor 
or no therapy  
 
no data on: informed 
consent, ethics 
committee, study 
location; dosing, 
validation of the 
questionnaire on self-
regulation 
Grossarth-
Maticek  
et al. 
2001(66) 
see above 
(same 
publication) 
breast ca UICC 
stage III A-III B 
n = 34 total 
   = 17 pairs 
(n = 34 or 17 pairs) 
 
n = 17 ISC 
 
n = 17 Ctrl 
 
ISC:  
standard therapy + ISC 
(dose and medication n/a) 
 
Ctrl:  
no Iscador, no data on 
other therapy 
1) change to the value for 
psychosomatic self-regulation:  
ISC from 2.92 to 3.70 vs Ctrl from 
2.87 to 2.99 
 
2) mean survival time: 
ISC longer (4.79 a) vs Ctrl (2.41 a) 
 
 
 
n.s. 
 
 
p = 0.02 
no data dropouts: none 
 
no data on: informed 
consent, ethics 
committee, study 
location; dosing, 
validation of the 
questionnaire on self-
regulation 
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Reference Type of 
study 
Diagnosis / 
therapeutic 
indication 
Patients 
included n / 
analysed (n) 
Treatment Results Statistics AE / side-effects Notes 
duration: 1974-1988 
Isorel (ISO) 
RCT / CT 
Cazacu  
et al. 
2003(86) 
prospective, 
randomised, 
ctrl 
 
A: 
Duke C: 16 + 
D: 5 
 
B: 
Duke C: 18, 
D: 11 
 
C: 
Duke C: 6, D: 
8 
 
(1997-2000) 
advanced 
colon tumour 
 
(Duke C: n = 40, 
Duke D: n = 24) 
 
(CTX with 
adjuvant 
biotherapy) 
n = 64 total 
 
n = 21 (= A) Ctrl 1 
 
n = 29 (= B) ISO  
 
n = 14 (= C) Ctrl 2 
 
duration: 6 cycles + 
3 mo follow-up  
Ctrl 1: 
OP + CTX (5-FU, 6 
cycles) 
 
ISO:  
OP + CTX (see above) + 
ISO (5 mg/kg BW i.v.-
infusion 3/wk, entire 
postoperative period) 
 
Ctrl 2:  
  OP 
1) MTT bioassay: 
concentration-dependent reduction of 
cell growth: 
1%: moderate (10%),  
10%: ED50 achieved 
15/20%: complete inhibition 
 
2) mean survival time: 
Duke C: ISO (757 d) vs Ctrl 1 (547 d) 
Duke C: ISO (757 d) vs Ctrl 2 (502 d) 
Duke D: Ctrl 1 (214 d) vs ISO (505 d) 
Duke D: Ctrl 2 (451 d) vs ISO (505 d) 
 
3) cumulative survival time according 
to Kaplan-Meier: 
Duke C 
Duke D 
 
 
 
p < 0.05 
no data 
no data 
 
 
p < 0.05 
p < 0.05 
p < 0.05 
p < 0.05 
 
 
 
n.s. 
n.s. 
side effects: 
CTX: diarrhoea, 
haematological toxicity 
Ctrl 1: n = 4/21 (19%) 
ISO: n = 0/29 
 
ISO: 
none observed 
no data on: dropouts, 
decision of the ethics 
committee, informed 
consent, study 
location, 
randomisation, ITT/PP, 
target criteria, duration, 
analysis stratified 
according to Duke 
Enesel et 
al. 2005(87) 
prospective, 
randomised, 
ctrl 
gastrointestinal 
cancer 
(heterogeneous 
group, stage II-III) 
n = 70 
 
n = 40 Isorel 
 
n = 30 Ctrl 
ISO:  
2 wks before and after 
OP 1 to 3 vials every 
other day s.c.  
 
Ctrl: 
not mentioned 
1) cellular immunity: 
leukozytes, lymphocytes, CD4/CD8, 
NK 
 
2) Karnofsky Index 
 
3) Analogic Scale of Anxiety  
no data 
(significant 
changes in the ISO 
group but 
no comparison  
between groups) 
not mentioned some data missing 
Lektinol (LEK) 
RCT / CT 
Semiglazov 
et al. 
2006(67) 
multicentre, 
randomised, 
ctrl (placebo), 
double blind 
Inclusion crit.: 
resectioned 
breast cancer  
TNM staging pT1-
T3 pN0-N+ pM0 
n = 337 (352) total 
 
n = 169 Lektinol 
 
n = 168 placebo 
 
duration: 
16 wk treatment 
LEK/Ctrl = 169/168 
 
24 wk treatment 
LEK/Ctrl = 103/104 
 
2 mo follow-up 
LEK: 
CTX (cyclo-phosphamide, 
methotrexate, 
fluorouracil) + LEK (30 
ng/mL, 2/wk s.c.) 
 
Ctrl: 
CTX + placebo 
1) FACT-G (16 and 24 weeks) 
LEK vs Ctrl 
 
2) GLQ-8, 5 and 3:  
LEK vs Ctrl 
 
3) Spitzer’s uniscale 
LEK vs Ctrl 
 
p < 0.0001 
 
GLQ-8 and 5:  
p < 0.0001; 
GLQ-3: p =  
0.0007 
p < 0.0001 
ADR: 
total: 
LEK= 82 (46.6%) 
Ctrl = 63 (35.8%) 
probable related: 
LEK = 17.6%; Ctrl = 1.7% 
 
local:  
LEK = 31; Ctrl = 2 
 
dropouts: 
1 due to allergic skin 
reaction in the LEK 
group  
 
QoL after 2 mo follow-
up without CTX:  
LEK sign. better than 
Ctrl 
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Reference Type of 
study 
Diagnosis / 
therapeutic 
indication 
Patients 
included n / 
analysed (n) 
Treatment Results Statistics AE / side-effects Notes 
without CTX 
Semiglasov 
et al. 
2004(68) 
prospective, 
multi-centre, 
randomised, 
pl-ctrl, db, 
parallel 
groups 
 
9 centres in 
Russia, 
Ukraine, 
Bulgaria 
Breast cancer 
stage II/III without 
metastases  
 
(p T1-T3, N0-N+ 
0-10 pos. lymph 
nodes, M0) 
 
(influence of 
mistletoe on QoL 
with adjuvant 
CTX) 
n = 272 total 
 
n = 66 LEK 1 
 
n = 65 LEK 2 
 
n = 64 LEK 3 
 
n = 66 Ctrl 
 
n = 261 ITT 
 
duration: 15 wks 
Ctrl:  
CTX (CMF,  4 cycles i.v. 
+ 10 mg Dx + 10 mg 
metoclopramide per d of 
the CTX) + pl 
 
LEK 1: 
CTX (see above) + LEK 
(0.5 mL 10 ng ML/ml 2 x 
/wk s.c.) 
 
LEK 2:  
CTX (see above) + LEK 
(0.5 mL 30 ng ML/ml 2 x 
/wk s.c.) 
 
LEK 3:  
CTX (see above) + LEK 
(0.5 mL 70 ng ML/ml 2 x 
/wk s.c.) 
1) GLQ-8 – sum score: 
total: 
confirmatory analysis: 
trend toward improvement in LEK 2 
and LEK 3 vs LEK1 and Ctrl; 
trend toward improvement in LEK 1 
and LEK 2 vs Ctrl; 
LEK 1 vs Ctrl; 
 
explorative comp. in pairs confirms 
LEK 2 vs Ctrl; 
LEK 1 vs Ctrl; 
LEK 3 vs Ctrl; 
 
2) Spitzer’s uniscale: 
total: 
LEK 2 vs Ctrl 
(after baseline adjustment) 
 
3) QLQ-C-30 EORTC: 
 
4) additional: 
haematology, use of 
antiemetic/analgesic medications and 
hospital days 
 
immune parameters (n = 43): 
dose-dependent increase in T-helper 
cells and CD4+ /CD8+ ratio after 4 
and 15 wk 
 
NK increase after 4 wk 
 
n.s. 
 
 
p = 0.0035 
 
p = 0.0017 
n.s 
 
 
p = 0.007 (ITT) 
n.s. 
n.s. 
 
 
n.s. 
p = 0.0016 
(p = 0.0021) 
 
n.s. 
 
 
 
 
n.s. 
 
 
 
 
p < 0.05 
 
p = 0.05 
4 AE: 
safety analysis: n = 272 (≥ 1 x 
study medication); 127 
patients (46.7%) with 244 AE 
(mult. occurrences in 1 patient 
counted as 1) 
 
LEK: 
- SAE:  LEK 3 - 1 x erythema,  
compl. recovery after 
discontinuation (but death due 
to necr. ulcerizing colitis, not 
related) 
- non-SAE (most common): 
dose-dependent local reaction 
(Ctrl 0%, LEK 1 9%, LEK 2 
17.9%, LEK 3 32.4%; possible 
/ probable related; no 
dropouts) 
- other AE: 4 patients (chills, 
muscle pain, headache, 
allerg. skin reaction or 
conjunctivitis - possible 
relation) 
 
CTX: 
white blood cell, RES 
disorders (Ctrl 20%, LEK 1: 
22.4%, LEK 2: 16.4%, LEK 3: 
20.6%) 
gastrointestinal (Ctrl 8.6%, 
LEK 1: 9%, LEK 2: 9%, LEK 
3: 14.7%) 
resistance mechanism 
disorders (Ctrl 5.7%, LEK 1: 
6%, LEK 2: 7.8%, LEK 3: 
8.8%) 
red blood cell disorders (Ctrl 
5.7%, LEK 1: 3.0%, LEK 2: 
3%, LEK 3: 11.8%) 
dropouts: 
11 withdrawal: 4 AE: (2 
Ctrl, 2 LEK), 4 patient 
request, 3 other 
reasons 
 
major protocol 
violations: n = 18 
(reason: 17 no 
compliance with the 
trial plan) 
 
insufficient information: 
consent, withdrawal (n 
= 11), PP 
 
no data on: study time, 
locations, blinding, 
validation of the 
questionnaires after 
translation into Russian 
and Bulgarian 
 
 
interim analysis with n 
= 178, p = 0.0172 
Notes: 
*: Divided analysis of the QoL with lower number of questionnaires starting at week zero.  
&: Lower incidence with EUR can be interpreted as relief provided by mistletoe therapy. But no overall conclusions can be drawn about side-effects with mistletoe therapy. 
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Abbreviations: 
ADR = adverse drug reaction; AE = adverse event; an = analysed; BW = body weight; ca = carcinoma; CI = Confidence interval; Ctrl = control; CMF = cyclophosphamide, 
methotrexate, fluorouracil; CR = complete remission; CRP = C-reactive protein; CTX = chemotherapy; d = day; DKG= Deutsche Krebsgesellschaft - German Cancer Society; DX 
= dexomethasone; EORTC = European Organisation for Research and Treatment of Cancer; EUR = Eurixor® (ML-I stand. mistletoe extract); FACT = Functional Assessment of 
Cancer Therapy Scale; FLIC = Functional Living Index - Cancer; HEL = Helixor; HR = hazard ratio; ISC = Iscador (depending on the host tree (see M, P, Q); ISO 0 Isorel; ITT = 
intention to treat; i.v. = intravenous; kg = kilogram; KPI = Karnovsky Performance Index; M = malus (Latin) apple; MC = mixed cellularity; ml = mililiter; ML = mistletoe lectin; mo = 
month; MR = mortality rate; MTT bioassay = tetrazolium salt based colourimetric assay to assess viability of cells; n = number of patients; n/a = not available; NaCl = sodium 
chloride; NC = not changed; Ney = Ney-Tumorin® (xenogenic peptide); n/d = no data; NK = natural killer cells; n.s. = not significant; OP = operation; OR = odds ratio; P = pinus 
(Latin) pine; pl = Placebo; PP = per protocol; PR = partial remissiom; Q = quercus (Latin) oak; QoL = quality of life; . q.o.d. = every other day; RTX = radiotherapy; SAE = serious 
adverse event; s.c. = subcutaneous; sign. = significant; ST= survival time; VEC= vindesine, epirubicin, cyclophosphamide; TCM = Traditional Chinese Medicine Index; vs = 
versus; wk(s) = week(s); y(rs) = year(s) 
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and components exhibit varying activity profiles, especially in 
regard to cytotoxic, anti-neoplastic, and immunomodulatory ef-
fects which seem to be dose-dependent.[19]
To ensure that the quality of each extract as a whole is as 
consistent as possible, mistletoe preparations today undergo a 
standardized manufacturing process (‘process standardized’). 
Yet, some newer preparations have been standardized to cer-
tain components as well (e.g. to ML; table 1). Standardisation 
means to adjust a drug powder or extract to a specified norm 
value indicating a minimum and maximum content, of a sub-
stance or substance group that is considered to determine its 
efficacy. Mistletoe preparations, no matter if standardized to 
ML or to the manufacturing process are available in differing 
dosages. To date, no generally accepted treatment scheme is 
available for mistletoe preparations but subcutaneous injec-
tions of the different preparations twice a week are found fre-
quently. Yet, empirically, older anthroposophic preparations 
are often administered at dosages that change rapidly, some 
according to a rhythmic sequence or in so called treatment se-
ries. In contrast, phytotherapeutic and newer anthroposophic 
preparations standardized to ML are usually administered at 
the same dosage over a longer treatment period before any 
adjustments are made.
Aspects of Preclinical Research 
From the large number of constituents in mistletoe extracts 
(table 1) those best described with pharmacological activities 
are lectins, viscotoxins, and polysaccharides.
Mistletoe Lectins: Lectins are glycoproteins of non-immune 
origin that bind carbohydrates reversibly and do not exhibit 
antibody functions. Intense investigations of mistletoe extracts 
have led to the isolation of three major MLs: ML-I binds 
preferentially to β-galactosides, ML-II to β-galactosides and 
N-acetylgalactosamins, whereas ML-III recognizes N-acetyl-
galactosamins [22]. MLs are the most investigated single 
component of mistletoe extracts. The cytotoxicity of different 
mistletoe extracts and MLs is well documented in numerous 
cultivated cancer cell lines, as is their immunomodulating re-
sponse [19, 23–25, 33]. The cytotoxic effects of the mistletoe 
extracts on tumour cells are not only due to the ribosome-in-
activating properties, but also depend on the direct induction 
of apoptosis [39–41]. Interestingly, induction of apoptosis by 
ML or extracts in cancer cells was found in concentrations of 
low cytotoxicity. However, the cytotoxicity and apoptosis-in-
ducing activity of mistletoe extracts seem strongly lectin-re-
lated [19, 40, 43]. 
As to immunomodulatory effects, the influence of different 
mistletoe extracts and MLs on the cells of the natural (innate) 
and of the specific immune system have been described in cul-
tured cell lines, animals and humans. NK cells deserve spe-
cial attention because they have been described as the target 
cells of mistletoe extract [19]. ML enhanced the cytotoxicity 
of NK cells in vitro [24] as well as the activation of macro-
phages. The animal models indicate that the immunomodu-
latory potency of mistletoe extracts and/or lectins is involved 
in the anti-tumour and anti-metastatic effect [45]. It can be 
assumed that lectin is the essential compound regarding the 
immunological activity of mistletoe extracts. However, its ef-
fect could be modulated by other components. A very impor-
tant property of mistletoe extracts and MLs is their ability to 
stimulate cytokine production in immunocompetent cells [19, 
25, 46]. In comparative studies with extracts standardized to 
ML and isolated lectins, the extent of cytokine release was 
higher with mistletoe extracts than with isolated lectin [46]. 
Recently, treatment with lectin in combination with ionising 
radiation resulted in an additive anti-proliferative effect on 
p53-deficient murine tumour cells and also on radiation-re-
sistant human adenocarcinoma SW480 cells [42]. In addition, 
the combination of ML and different chemotherapeutic drugs 
caused an additive and/or synergistic effect on the cytotoxicity 
towards lung cancer cells [47]. These results reflect that the 
combination of mistletoe therapy with chemotherapy and/or 
radiotherapy gives hope for new clinical perspectives. 
Viscotoxins: Viscotoxins are basic polypeptides related to 
a group of thionins [26]. They have a low molecular weight 
of about 5 kDa. In contrast to the numerous studies on the 
cytotoxicity of ML only few studies have investigated the 
toxicity of viscotoxins, but induced cell death much faster 
by damaging the cell membrane, leading to necrosis [44]. On 
human lymphocytes viscotoxins exerted rapid membrane-per-
meabilizing effects accompanied by the generation of reactive 
oxygen intermediates, which led to necrotic cell death [27]. 
Apart from the cytotoxic effects of viscotoxins, enhancement 
of phagocytosis and oxidative bursting of human granulocytes 
were described [28], as well as increased natural killer (NK) 
cell-mediated toxicity [29]. 
Oligo- and Polysaccharides: Amongst the compounds with 
high molecular weights, most probably the polysaccharides 
are the active components [30]. Rhamnogalacturonan sam-
ples from commercially available extracts of mistletoe grown 
on different host trees (apple tree, oak, pine) demonstrated 
a dose-dependent enhancement of cytotoxicity to NK, lym-
phocyte activated killer (LAK) and activated CD3+ T cells. 
The most prominent properties of mistletoe extracts are 
their immunomodulatory [19, 31] and cytotoxic effects [23] in 
cultured cells and animals studies. Studies with the isolated 
components of mistletoe extracts are useful in understanding 
the molecular mechanisms underlying the beneficial effect of 
the therapeutic preparation, however they do not take into 
account the positive or negative additive effect of different 
components in the final preparation, e.g. with polysaccharides 
and viscotoxins [23, 32]. Recently, new peer-reviewed articles 
have been published, representing the most updated collec-
tion of translational mistletoe research [34–38]. 
In addition, the protective effect of mistletoe extracts 
should be mentioned: they improved DNA repair of lym-
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phocytes in breast cancer patients [48] and prevented activa-
tion marker depression on T cells mediated by cyclophospha-
mid [49]. However, single substances (i.e. ML, viscotoxin) did 
not prevent this depression. 
Aspects of Clinical Research
In 1989, Kiene published the first comprehensive review of the 
available very heterogeneous prospective and retrospective, 
controlled and uncontrolled clinical trials on mistletoe, and 
revised it in 1996 [50, 51]. The authors considered only one 
third of the studies as meaningful, not least because of con-
siderable weaknesses in methodology and data presentation. 
They evaluated the results as being indications of relevant 
efficacy and therapeutic superiority when mistletoe prepara-
tions were included in the treatment of patients with cancer-
ous tumours. In 1994, Kleijnen and Knipschild [52] published 
another systematic review. The authors considered only 11 of 
the studies to be methodologically sound, and therefore, rele-
vant. However, since the methodological quality of the studies 
was on the whole unsatisfactory, the authors considered the 
data as insufficient to give evidence for anti-neoplastic effi-
cacy. In 2003, Ernst and colleagues [53] published a systematic 
review which included only 10 randomised controlled trials 
(RCTs) and emphasized the methodological deficiencies of 
most of the studies. Yet, they stated that the methodologically 
weaker studies indicated that the use of mistletoe provides 
some benefit with respect to quality of life (QoL), whereas 
the methodologically more sound studies (defined by qual-
ity score [54]) did not confirm this. Also in 2003, Kiene and 
Kienle published a comprehensive systematic review [2, 55] 
in which they not only included RCTs, but also all prospective 
clinical trials they found (23). A complicated 4-level quality 
score comprising 11 items was used. This assessment demon-
strated beneficial effects in terms of survival (8 studies), over-
all QoL (n = 3), and reduction of side-effects of the oncologi-
cal therapy (n = 3), yet 1 study indicated a negative trend for 
disease-free survival and in 4 no effect on survival. The gener-
ally positive assessment of the study quality clearly contradicts 
the result of Ernst et al. [53]. In 2007, the systematic review of 
Kienle et al. on 25 trials with anthroposophic mistletoe prepa-
rations reports – while stating the known quality limitations 
– a benefit on survival in 5 of 10 RCTs but points out that the 
best evidence of efficacy of mistletoe therapy remains for the 
improvement of QoL (3 of 5 RCTs) and the reduction of side-
effects of cytotoxic therapies (e.g. chemotherapy, radiation: 
3 of 5 RCTs, 2 non-RCTs). The latest systematic review of 
Horneber et al. [56] drew basically similar conclusions on the 
improvement of QoL due to additional mistletoe therapy. 
This list of reviews on mistletoe shows, that up to date the 
various authors – despite of their different in- and exclusion 
criteria or rating parameters – come to a similar result concern-
ing a possible benefit on QoL. But the academic discussion is 
continued without taking into account the patients’ needs and 
giving constructive arguments for future research. Moreover, 
Ernst’s sceptical estimation of the benefit of mistletoe therapy 
was intensified in a fiercely discussed editorial, where he char-
acterized mistletoe therapy as ineffective according to current 
publications [57]. However, since the above mentioned sys-
tematic reviews were completed new clinical trials have been 
published [58, 59]. Therefore, this paper gives an updated re-
view. Above all, it aims to serve cancer patients by taking into 
account what they value most in face of the available clinical 
evidence and a rational for the mode of action.
Materials and Methods 
Potentially relevant clinical trials were searched in the following data-
bases (1968 – February 2007): AMED, BIOETHICSLINE, BIOSIS, 
CATLINE, CISCOM, Cochrane Complementary Medicine (field regis-
try of randomised clinical trials and controlled clinical trials), EMBASE, 
INT. HEALTH TECHNOLOGY, MEDLINE. The search terms used 
were: abnoba, cancer, clinical trial, Eurixor, Helixor, Iscador, Iscucin, Iso-
rel, Lektinol, malignancy, mistletoe, mistletoe lectins, Plenosol, Viscum, 
Vysorel. As inclusion criterion the respective publications had to evaluate 
at least process standardized mistletoe preparations either in randomised 
or comparative controlled trials or cohort studies (due to external valid-
ity) in systemic interventions, e.g. subcutaneous (and/or per infusion) in 
patients with cancer.
In addition, the reference lists of all relevant articles and the following 
journals (which are currently not, or only partially, listed in databases) 
were hand searched: Erfahrungsheilkunde, Therapeutikon (discontin-
ued), Ärztezeitschrift für Naturheilverfahren, Schweizerische Zeitschrift 
für Ganzheitsmedizin. The languages were limited to German, French 
and English.
Studies that investigated intravenous injection, intravesicular or in-
trapleural application of mistletoe preparations were excluded, as were 
studies with insufficient or incomprehensible explanations of study condi-
tion, patient number, or survey instrument. Incomplete information about 
dosage (mostly in older studies) was no reason for exclusion because the 
dosage of mistletoe can change repeatedly over the course of treatment 
and constant dosing therefore is not commonly practiced. Publications of 
abstracts or phase I and II studies were not included. If published more 
than once, the publication with the more detailed description or complete 
publication of the results or the publication from a peer-reviewed jour-
nal was selected. The use of MLs as a single substance was also excluded 
because such preparations are investigational drugs and have not been 
approved for use as medicinal products. Data extraction and validation 
were performed by two authors and checked by a third author using 
standardized, predefined criteria: study design, sample size, patient de-
scription, interventions, primary endpoints and main results. The Jadad 
Score (internal validity, i.e. randomisation, blinding) was not used to 
evaluate methodological quality [54] because we included trials with ex-
ternal validity (e.g. observational) as well, and so it would not have been 
a general quality score. The decision to include observational studies was 
based on the fact that problems with recruiting patients for randomised 
trials on mistletoe have repeatedly been reported [60–62]. Hence, obser-
vational trials which have been performed in the last years, give at least 
some additional information close to daily medical practice. Additionally, 
one could question the possible blinding of trials on mistletoe because 
patients might know from various sources that injecting mistletoe extracts 
can cause local reactions. As a matter of fact, it has been published that 
the majority of study participants were able to correctly identify whether 
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they had received mistletoe or placebo [61] and local side-effects are 
 common [75]. Moreover, awareness of randomisation can controvert 
greatly a patient’s intention for a specific therapy. Many patients de-
liberately choose mistletoe as part of their cancer treatment. Explicitly 
choosing a therapy that contradicts a patient’s own subjective vision [63] 
can be a significant factor regarding efficacy, which seems specifically 
 associated with the use of mistletoe and cannot be casually transferred 
to comparable therapies or placebo treatments. Therefore, requirement 
for randomisation can deter a considerable percentage of patients intend-
ing to use mistletoe treatment from participating in a study [60, 61]. This 
relativises the principle of randomisation as a criterion of quality in the 
context of mistletoe treatment. Nevertheless, table 2 (c.f. www.karger.
com/doi/10.1159/000226249) enables a reproducible, multidimensional 
assessment of quality without using a formal rating score but still shows 
the various weaknesses and potential strengths of each trial due to the de-
tailed information. However, we listed the trials according to the different 
mistletoe preparations to see if the evidence prevails for one or another.
Results 
19 publications of 18 different trials (approximately 6,800 par-
ticipants) published in German or English met the inclusion 
criteria (table 2; 1 study [64] was included even though the 
authors classified it as phase II because it contained a refer-
ence group).
Study Design: The quality of the randomised and obser-
vational trials varied but was often low. Additionally, across 
the studies, interventions and outcome parameters varied 
considerably. Therefore, the heterogeneity of the trials or in-
sufficient data presentation still makes a meta-analysis impos-
sible. Interestingly, an overview of the clinical trials indicates 
a change in outcome parameters over the decades: Until the 
late 1980s, research primarily focused on survival time and in-
cidence and/or duration of remissions. Not until the 1990s, as-
pects of QoL were included in the studies [65–68]. From 2000 
onwards, research seems to concentrate on QoL (table 2). 
Study Outcome: The abovementioned change in clinical re-
search might be related to the results one can carefully extract 
from the studies: The data are inconclusive about whether life 
expectancy is increased. Yet, regarding QoL several studies 
indicate an improvement (e.g. improved physical and psycho-
logical wellbeing). The present findings give ground for the 
assumption that the evidence of the role of mistletoe therapy 
in a complex oncological setting might be that of a supportive 
treatment, which was the situation in all the reviewed stud-
ies. Yet, some studies with high internal validity did not show 
such a benefit. However, as mistletoe therapy can stimulate 
the cellular part of the immune system (e.g. NK cells, mac-
rophages) this could partly explain physical improvements 
which can contribute to an improvement of QoL in patients 
with cancer along with current oncological therapy. Neverthe-
less, QoL was measured by various instruments in the trials 
(one- and multidimensional questionnaires, mostly patient-
rated but also questioning by third parties [59, 69–73]; table 
3) and apart from physiological improvements, other dimen-
sions contributing to QoL, like psychological ones, have not 
yet been examined systematically (e.g. patients’ autonomy, 
theory of self-regulation). 
Additionally, some trials state that mistletoe therapy im-
proves patients’ tolerability of chemotherapy and radiother-
apy. This is discussed by others as well [74] but has to be con-
firmed in future trials.
The treatment duration of mistletoe therapy ranged from 
weeks to years as it might have depended on the respective 
treatment situation. In practice and in the course of time, a 
therapy sometimes becomes a form of secondary or tertiary 
prophylaxis against metastases and recurrence. However, 
treatment duration and postulated aspects of prophylaxis have 
not been sufficiently tested in the clinical trials.
Mistletoe Preparations: In all the studies reviewed, 5 dif-
ferent mistletoe preparations either standardized to process 
or MLs were used (table 1). In German-speaking European 
countries some of these preparations are registered by health 
authorities as drugs and reimbursed by general health insur-
ance (e.g. in Switzerland different preparations of Iscador and 
Helixor). So far, the possible benefit on QoL does not seem to 
be limited to a specific mistletoe preparation, although some 
pharmacological effects might give ground for the administra-
tion of extracts standardized to ML. But at present, for some 
mistletoe preparations standardized to ML (e.g. Iscador spec.) 
no clinical trials are available. Therefore, to aid a compre-
hensive clinical assessment of the current state of evidence, it 
seems justified to use the term ‘mistletoe therapy’ as an um-
brella term for the use of the different mistletoe preparations. 
Mistletoe therapy can be defined as the therapeutic use of the 
parenteral medicinal products made from mistletoe which are 
reviewed in this paper. Using this term gives some kind of a 
rational to search for an overall outcome parameter that can 
be used to describe or to postulate an efficacy common to the 
different preparations and treatment plans used in the trials. 
This can help to find the role of this treatment for patients in 
an oncological setting.
Cancer Entity: The different mistletoe preparations were 
studied in a variety of solid cancer diseases such as: often 
breast and colorectal, but also glioma, abdominal, pancreatic, 
bladder, ovarian, cervical, bronchial/lung cancer, head/neck 
carcinoma, and malignant melanoma. The possible benefit on 
QoL does not seem to be linked to a specific tumour entity 
which might give ground for the role of mistletoe as a sup-
portive treatment improving QoL in a complex oncological 
setting.
Safety: In terms of safety, the available studies indicate that 
mistletoe therapy is well tolerated although a systematic eval-
uation is lacking in some trials. Serious adverse events (AEs) 
definitely related to mistletoe therapy were not reported ex-
cept for 1 patient with angiooedema [71]. AEs related to mis-
tletoe therapy were: (a) local (at the injection site): e.g. pruri-
tus, erythema, induration; (b) systemic: e.g. flu-like syndrome, 
fatigue, fever, and headache. The data about the incidence 
of AEs ranges widely. Especially in mistletoe therapy it is a 
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matter of ongoing debate whether some of the most common 
AEs, the local ones are considered or interpreted as undesired 
or actually desired (e.g. kind of surrogate for general physi-
ological response). According to this, the data about the inci-
dence of side effects ranges widely. Only a few of the studies 
reviewed here [58, 70] explicitly differentiate between local 
and systemic side-effects. The cumulated numbers are 17.5% 
for total side-effects, 15.9% for local, and 1.6% for systemic 
side-effects. These data are more or less comparable to the 
result of a previous systematic review on AEs under mistletoe 
therapy which showed local reactions between 0.9–43% and 
systemic reactions between 0.8–4% depending on the inter-
pretation whether being desirable or undesirable [75]. Aller-
gic reactions occurred but the frequency was approximately 
<1%. These results were confirmed by the data of authorities 
and manufacturers, as far as they were available [75]. 
Discussion 
Clinical research on the use of mistletoe preparations in on-
cology has reached a complex state with the different system-
atic reviews (e.g. varying inclusion criteria, quality ratings, 
mistletoe preparations) which indicate an improvement of 
QoL. The present review of randomised and observational 
clinical trials of supportive ‘mistletoe therapy’ (as defined 
above) next to standard oncological treatments shows a pos-
sible benefit on patients’ QoL, a reasonable safety profile but 
inconsistent data on survival or anti-tumour effects. One has 
to point out, that to date all these findings seem to be more or 
less independent of the tumour entity examined or the mis-
tletoe preparation used, although other authors recently have 
postulated that the benefit might be specific to patients with 
breast tumours [56]. No definite conclusion can be drawn on 
dosing or treatment duration although clinical and pharma-
cological data support the use of low-dose ML-standardized 
mistletoe extracts over several months.
Table 3. QoL instruments used in the clinical trials reviewed [76–81]
Instrument Design User / time necessary / 
rating / since
Multidimensional questionnaires rated by patients
EORTC QLQ-C-30 6 areas (func., phys., soc., psych., global, therapy)
30 questions, 1–4 points
adults / 5–15 min / 
↓ points = ↑ QoL / 1993 
Functional Assessment
of Cancer Therapy – General  
(FACT-G)
5 areas (phys., soc., emo., func., relationship with 
physician)
28 questions (last 7 days), 0–4 points
adults / 5–10 min / 
↑ points = ↑ QoL/1987–1992
Functional Living Index: Cancer  
(FLIC)
25 areas (phys., func., soc., psych., therapy)
2 questions, LAS
adults / <10 min / 
↑ LAS = ↑ QoL / 1984
Global Life Quality (GLQ-8) 2 areas (phys., emo.)
8 questions, LAS
adults / 3–5 min / 
↑ LAS = ↓ QoL / 1990 / during chemotherapy
Medical Outcome Study (MOS) 36-Item 
Short Form (SF-36) / SF-12
8 areas (phys. function/limitation, soc., pain, mental, 
emo., vitality, perception)
36 questions, 1–6 points
from age 14 / 15 min / 
↑ points = ↓ QoL / 1992
Multidimensional questionnaires rated by third party
Spitzer Quality of Life Index  
(QLI)
5 areas (activity, daily living, health, support/soc., 
outlook/emo.)
5 questions, 0–2 points
adults / 5 min / 
↑ points = ↑ QoL / 1981
One-dimensional questionnaire rated by third party
Karnofsky Performance Status Scale  
(KPS)
1 question (func. 0–100 %) adults / 2 min / 
↑ % = ↑ QoL / 1949
does not comply with today’s definition of QoL
Spitzer Quality of Life Uniscale Cumulative (phys., mental, emo.)
1 question
Visual Analogue Scale (VAS)
adults / 1 min / 
↑ VAS= ↑ QoL / 1981
Traditional Chinese Medicine Score  
(TCM-score)
1 area (phys.)
5 questions
0–4 points
–* / –* / 
↓ points = ↑ QoL / –*
emo = Emotional; func. = functional; LAS = linear analogue scale; phys. = physiological; psych. = psychological; soc. = social. 
* = No published data about validation available and no response by authors. 
↑ = High; ↓ = low.
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One has to be aware, that the trials reviewed were per-
formed under different prevailing regulations and hence di-
verging quality standards (e.g. International Committee on 
Harmonisation, Good Clinical Practice).
The shortcomings of the present review might be that no 
validated rating system was employed to measure study qual-
ity and that it was not limited to randomised trials. Yet, if one 
keeps in mind the problems involved in recruiting patients for 
randomised trials on mistletoe therapy and the questionabil-
ity of successful blinding due to very common local reactions, 
it seems justified to include observational studies and conse-
quently, to do without rating internal quality.
The strength of this review is that it lists the studies accord-
ing to the different preparations. This enables the analysis 
that up to date the results are not triggered by a specific mis-
tletoe preparation, and therefore, gives some ground to speak 
of ‘mistletoe therapy’. Furthermore, by mapping the research 
evidence from the clinical trials reviewed with the given sum-
mary of main data concerning the mode of action and patients’ 
values and adding our clinical experience, we try to bridge the 
gap between research and practice which sometimes occurs 
due to a simplistic view of evidence-based medicine (EBM) 
although its promoters define EBM in a very complex way 
(i.e. research evidence, physician’s expertise, patient’s needs 
and values) [82, 83].
Aspects Due to the Mode of Action: A pharmacologically 
oriented view indicates that for immunomodulatory effects of 
mistletoe therapy relatively low dose preparations have to be 
used. Such effects have been observed in healthy volunteers 
as well, yet can be expected to be smaller under oncological 
treatment. However, to achieve anti-neoplastic (e.g. pro-ap-
optotic, cytotoxic) effects in clinical trials, much higher doses 
may be required. One would have to bear in mind, however, 
that due to cytotoxic effects of higher concentrations (e.g. 
eventually from regular single doses of 50 ng ML twice weekly 
upwards) side-effects (e.g. lymphocytopenia) might have to be 
expected as well, which could finally contradict QoL (e.g. im-
munosuppressive effects). Therefore, haematological controls 
(e.g. neutrophil subpopulations) are indicated under mistletoe 
therapy.
Patient Values and Aspects in Regard to QoL: Next to the 
pharmacologically explainable immunomodulatory effects 
and consequently possible physical improvements (e.g. in-
creased appetite, better sleep, less fatigue, lower susceptibility 
to respiratory infections), one needs to consider psychological 
effects which can contribute to the efficacy of mistletoe ther-
apy. In surveys among oncological patients, those using CAM 
(i.e. predominantly mistletoe therapy) stated a less overall 
deterioration of their health status than non-users, and CAM 
use was associated with better coping with their disease [8]. 
Other surveys have stated that patients’ motivations of CAM 
use are e.g. maintenance of autonomy, a conscious use of re-
sources, especially a support of the immune system/resistance 
or generally a personal contribution to therapy or reduction 
of side-effects [5]. These data show the importance of patient-
centred criteria especially in supportive CAM treatments and 
the present review supports this approach. In practice, a clos-
er look on terms such as ‘resistance’ shows, that in a patient’s 
perspective, these are by no means limited to the ‘immune 
system’ but include multidimensional (i.e. ‘holistic’) aspects. 
‘Resistance’ appears to be a complex metaphor for numer-
ous processes and ideas meaningful to a patient in securing 
his individual existence. Besides a more or less specific impact 
on the immune system to fight cancer and infections, other 
aspects play an important role, e.g. to overcome physical and 
psychological weakness, anxiety, doubt, powerlessness. Treat-
ment with mistletoe preparations might offer both ‘biochemi-
cal’ and individually definable assistance in coping with can-
cer. Mistletoe therapy, carefully chosen by both patient and 
physician could help considerably to initiate or increase au-
tonomy in dealing with the disease. Various lines of thoughts 
and conceptions in CAM / anthroposophic medicine may play 
a decisive role. 
During the course of their disease, many patients have to 
decide whether to start mistletoe therapy based on their own 
considerations or on the advice of others. Of course, this may 
be related to expectations that are based on the patients’ men-
tal and emotional attitudes towards life, their cancer disease 
and to some degree also on their knowledge and awareness 
of experimental research. Empirical reports from other pa-
tients and their relatives also play a large role. Including the 
patients’ ideas (e.g. on how to deal with the tumour, and as-
sociated threats and limitations, how to contribute to recovery 
and probably healing) is one general factor affecting efficacy. 
The subjective selection of mistletoe therapy may be relevant 
to the treatment. Also, patients may take over a very active 
role in their treatment by administering the individual dose 
s.c. themselves. This type of therapy can contribute greatly, 
beyond palliative and supportive effects, to individual re-
source allocation (e.g. mobilisation of hope and strength). 
On a functional level, the concept of activating individual re-
sources (e.g. immunomodulation) focuses on a treatment at-
tempt that activates parts of the body, in this case an at least 
partially operational – and therefore influenceable – immune 
system. This approach enables patients to perceive themselves 
not only as someone who suffers from cancer (e.g. disease as a 
deficit), but as individuals that therapeutically activate organs 
of their body. Self-administering of such a supportive therapy 
with definable biological effects and consequently, a physical 
efficacy which fits into a patient’s range of treatment strate-
gies, might contribute to strengthen his or her autonomy. It 
remains to be examined how such feedback loops of physical 
and psychological effects can be made operational.
Patients’ Safety, Interactions: Additionally to the above-
mentioned results on AEs it seems necessary to point out that 
pharmacological studies on possible interactions with mistle-
toe therapy are widely lacking [84]. If in terms of QoL its main 
efficacy is in the area of immunomodulatory effects (cellular 
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immunity) – next to psychological effects – an interaction with 
phase II enzymes seems unlikely, but nevertheless would have 
to be examined. Up to date only one interim report of a phase 
I study with the concomitant use of Gemcitabine/Helixor in 
16 patients (mamma, pancreas, colorectal cancer) concerning 
pharmacokinetics, dose-limiting toxicity and AE is available 
and no significant changes (e.g. area under the curve, plasma 
concentration) have been found [85]. Pharmacokinetic trials 
examining possible interactions with other chemotherapies as 
well as hormone or immune therapy would be useful to be 
able to increase patients’ safety.
Despite the large number of preclinical research data on 
anti-neoplastic effects (e.g. cytotoxic, anti-tumour), the results 
of one working group about the possibility to experimentally 
stimulate the growth of tumour cells with mistletoe or individ-
ual mistletoe substances were stressed repeatedly (e.g. tumour 
proliferation in isolated cell lines and increased pulmonary 
metastatic formation in an animal model, each with isolated 
MLs at a low dosage range). But these results could not be re-
produced by other groups, neither with isolated MLs nor with 
whole extracts; and in some of the reproduced experiments, 
comparable doses even resulted in inhibited tumour growth 
[86–88]. Yet, regardless of experimental trials, we consider 
mistletoe therapy a contraindication at least in patients with 
acute leukaemia (lack of clinical trials) due to immunomodu-
latory effects (e.g. possible stimulation of leukocytes). 
Future Research: Under the premises that mistletoe thera-
py can have a benefit on QoL it seems worthwhile to consider 
to leave former research focuses (e.g. survival, anti-tumour ef-
fects) aside and to optimise research on aspects of QoL (e.g. 
physiological and psychological wellbeing). The current gold 
standard in EBM, the RCT, does not include studies based 
on patient-centred criteria. Furthermore, some criteria of in-
ternal quality (i.e. randomisation, blinding) aim to exclude 
fundamentally subjective factors that probably affect mistle-
toe therapy (e.g. patient’s preference, psychological, mental, 
spiritual viewpoints). Therefore, a modern evaluation would 
have to make use of study types and outcome instruments 
that address research questions according to mistletoe ther-
apy as a patient-centred supportive treatment. Although to 
date, a generally accepted definition of QoL does not exist, 
the following may give a hint on the different aspects that may 
contribute to a patient’s QoL: ‘QoL is the satisfaction of an 
individual with his or her physical, emotional, spiritual, social’ 
and, one might add, psychological situation [89]. In the face of 
such a complex, yet realistic definition, only multidimensional, 
patient-rated, disease-specific, and validated questionnaires 
seem suitable to evaluate the benefit of mistletoe therapy on 
QoL in prospective observational trials. Questions specific 
to the use of mistletoe could be added. To acquire a better 
knowledge about dosing mistletoe preparations standardized 
to ML or to the manufacturing process solely should also be 
studied in different concentrations, because the clinical re-
search evidence to date does not support the administration 
of high concentrations. Connected with dosing is the question 
of the duration of the treatment which would probably have 
to be examined in the range from months up to 1 year start-
ing with or during standard oncological treatment. It would 
probably be useful to analyse certain research questions like 
immunomodulatory and cytotoxic effects of low and high dos-
ages in healthy volunteers first, in order to corroborate these 
data and to develop further strategies for patients. 
Conclusion
According to the available evidence in the field of mistle-
toe therapy, the present review gives some ground for an 
approach in order to serve the patient: Under the aim of a 
supportive therapy main concerns of cancer patients can be 
respected, if clinical research evidence is combined with a ra-
tional for the mode of action, the clinical expertise of the phy-
sician in charge of the therapy, and by integrating patients’ 
values. In general, mistletoe therapy is not an ‘alternative’ to 
oncological therapies (e.g. operation, chemo- or radiothera-
py). But it seems safe and beneficial for the improvement of 
QoL in patients with solid tumours. However, there is a lack 
of research to consolidate its supportive efficacy as a patient-
centred care in a complex oncological setting. This has to be 
studied at least in prospective observational trials (using dif-
ferent dosages, preparations, time intervals) and evaluated 
with validated, multidimensional patient-rated QoL instru-
ments.
Online Supplemental Material 
Table 2. Summary of clinical trials with mistletoe therapy – listed accord-
ing to different preparations (www.karger.com/doi/10.1159/000226249)
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